Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension

NCT05437224 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Ambrisentan

Sponsor

RenJi Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]